Essential CNS Drug Development
Herausgeber: Kalali, Amir; Preskorn, Sheldon; Kwentus, Joseph
Essential CNS Drug Development
Herausgeber: Kalali, Amir; Preskorn, Sheldon; Kwentus, Joseph
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Presents the complicated process of CNS drug development in a way that is engaging and informative for professionals and students.
Andere Kunden interessierten sich auch für
- Stephen M. StahlStahl's Essential Psychopharmacology276,99 €
- K. W. M. FulfordEssential Values-Based Practice61,99 €
- Antiepileptic Drugs78,99 €
- Peptide Transport and Delivery into the Central Nervous System77,99 €
- Younggil KwonHandbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists114,99 €
- Christophe WiartEthnopharmacology of Medicinal Plants237,99 €
- David WilliamsEssential Biomaterials Science121,99 €
-
-
-
Presents the complicated process of CNS drug development in a way that is engaging and informative for professionals and students.
Produktdetails
- Produktdetails
- Verlag: Cambridge University Press
- Seitenzahl: 226
- Erscheinungstermin: 7. Juni 2012
- Englisch
- Abmessung: 240mm x 161mm x 17mm
- Gewicht: 510g
- ISBN-13: 9780521766067
- ISBN-10: 0521766060
- Artikelnr.: 33214789
- Verlag: Cambridge University Press
- Seitenzahl: 226
- Erscheinungstermin: 7. Juni 2012
- Englisch
- Abmessung: 240mm x 161mm x 17mm
- Gewicht: 510g
- ISBN-13: 9780521766067
- ISBN-10: 0521766060
- Artikelnr.: 33214789
Preface; 1. History of CNS drug development Sheldon H. Preskorn; 2.
Regulatory issues Gwen L. Zornberg; 3. Pre-clinical development Alan J.
Cross and Frank D. Yocca; 4. Phase I trials: from traditional to newer
approaches Matthew Macaluso, Michael Krams and Sheldon H. Preskorn; 5.
Phase II development and the path to personalized medicine in CNS disease
Douglas E. Feltner and Kenneth R. Evans; 6. CNS drug development ¿ Phase
III Judith Dunn, Penny Randall and Amir Kalali; 7. Statistics issues
relevant to CNS drug development Craig H. Mallinckrodt, William R. Prucka
and Geert Molenberghs; 8. Clinical trials management at company level Nuala
Murphy; 9. Clinical trials management at the site level Joseph Kwentus; 10.
Medical writing for CNS indications Ginette Nachman; 11. Dissemination of
clinical trial information: multiple audiences, multiple formats Leslie
Citrome; 12. The importance of treating cognition in schizophrenia and
other severe mental illnesses: background, strategies, and findings to date
Philip D. Harvey and Richard S. E. Keefe; 13. Leveraging disruptive
technologies to drive innovation in CNS clinical drug development Penny
Randall, Judith Dunn and Amir Kalali; Index.
Regulatory issues Gwen L. Zornberg; 3. Pre-clinical development Alan J.
Cross and Frank D. Yocca; 4. Phase I trials: from traditional to newer
approaches Matthew Macaluso, Michael Krams and Sheldon H. Preskorn; 5.
Phase II development and the path to personalized medicine in CNS disease
Douglas E. Feltner and Kenneth R. Evans; 6. CNS drug development ¿ Phase
III Judith Dunn, Penny Randall and Amir Kalali; 7. Statistics issues
relevant to CNS drug development Craig H. Mallinckrodt, William R. Prucka
and Geert Molenberghs; 8. Clinical trials management at company level Nuala
Murphy; 9. Clinical trials management at the site level Joseph Kwentus; 10.
Medical writing for CNS indications Ginette Nachman; 11. Dissemination of
clinical trial information: multiple audiences, multiple formats Leslie
Citrome; 12. The importance of treating cognition in schizophrenia and
other severe mental illnesses: background, strategies, and findings to date
Philip D. Harvey and Richard S. E. Keefe; 13. Leveraging disruptive
technologies to drive innovation in CNS clinical drug development Penny
Randall, Judith Dunn and Amir Kalali; Index.
Preface; 1. History of CNS drug development Sheldon H. Preskorn; 2.
Regulatory issues Gwen L. Zornberg; 3. Pre-clinical development Alan J.
Cross and Frank D. Yocca; 4. Phase I trials: from traditional to newer
approaches Matthew Macaluso, Michael Krams and Sheldon H. Preskorn; 5.
Phase II development and the path to personalized medicine in CNS disease
Douglas E. Feltner and Kenneth R. Evans; 6. CNS drug development ¿ Phase
III Judith Dunn, Penny Randall and Amir Kalali; 7. Statistics issues
relevant to CNS drug development Craig H. Mallinckrodt, William R. Prucka
and Geert Molenberghs; 8. Clinical trials management at company level Nuala
Murphy; 9. Clinical trials management at the site level Joseph Kwentus; 10.
Medical writing for CNS indications Ginette Nachman; 11. Dissemination of
clinical trial information: multiple audiences, multiple formats Leslie
Citrome; 12. The importance of treating cognition in schizophrenia and
other severe mental illnesses: background, strategies, and findings to date
Philip D. Harvey and Richard S. E. Keefe; 13. Leveraging disruptive
technologies to drive innovation in CNS clinical drug development Penny
Randall, Judith Dunn and Amir Kalali; Index.
Regulatory issues Gwen L. Zornberg; 3. Pre-clinical development Alan J.
Cross and Frank D. Yocca; 4. Phase I trials: from traditional to newer
approaches Matthew Macaluso, Michael Krams and Sheldon H. Preskorn; 5.
Phase II development and the path to personalized medicine in CNS disease
Douglas E. Feltner and Kenneth R. Evans; 6. CNS drug development ¿ Phase
III Judith Dunn, Penny Randall and Amir Kalali; 7. Statistics issues
relevant to CNS drug development Craig H. Mallinckrodt, William R. Prucka
and Geert Molenberghs; 8. Clinical trials management at company level Nuala
Murphy; 9. Clinical trials management at the site level Joseph Kwentus; 10.
Medical writing for CNS indications Ginette Nachman; 11. Dissemination of
clinical trial information: multiple audiences, multiple formats Leslie
Citrome; 12. The importance of treating cognition in schizophrenia and
other severe mental illnesses: background, strategies, and findings to date
Philip D. Harvey and Richard S. E. Keefe; 13. Leveraging disruptive
technologies to drive innovation in CNS clinical drug development Penny
Randall, Judith Dunn and Amir Kalali; Index.